The presentation of positive long-term data typically has a favorable impact on a biotech company's stock price as it suggests potential for successful drug development and future revenue streams. Given that rusfertide is a key asset in Protagonist's pipeline, the news is highly relevant and important to investors. The confidence score reflects the typical market response to positive clinical trial results, although the actual impact can be influenced by broader market conditions and investor sentiment.